Finance

Beta
Lists
HALO:NASDAQ
Halozyme Therapeutics, Inc.
$72.06
+1.27%
(+0.90) 1D
Jun 25, 1:37:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HALO...
Open
$71.38
High
$73.53
Low
$71.38
Mkt. cap
8.55B
Avg. vol.
1.95M
Volume
645.90K
P/E ratio
25.92
52-wk high
$82.22
52-wk low
$51.06
EPS
$2.78
Beta
0.88
Shares outstanding
118.61M
No. of employees
423
Open
$71.38
High
$73.53
Low
$71.38
Mkt. cap
8.55B
Avg. vol.
1.95M
Volume
645.90K
P/E ratio
25.92
52-wk high
$82.22
52-wk low
$51.06
EPS
$2.78
Beta
0.88
Shares outstanding
118.61M
No. of employees
423
News stories
From sources across the web
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com
Analyst Ratings
Based on 6 analysts giving stock ratings to HALO in the past 3 months
Buy
Buy
3
Hold
2
Sell
1
12 month forecast
Based on 6 Wall Street analysts offering 12 month price targets for HALO in the last 3 months.
Highest
Current $72.06
$96.00 (+33.23%)
Average
$81.00 (+12.41%)
Lowest
$57.00 (-20.89%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$95.00
+31.8%
06/16/2026
Corinne Johnson
Goldman Sachs
Sell
Maintained
$57.00
-20.9%
06/14/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$93.00
+29.1%
06/15/2026
Mohit Bansal
Wells Fargo
Hold
Reiterated
$75.00
+4.1%
06/15/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
$70.00
-2.9%
05/20/2026
Brendan Smith
TD Cowen
Buy
Maintained
$96.00
+33.2%
05/11/2026
Robert Wasserman
Benchmark Co.
Buy
Maintained
$90.00
+24.9%
02/19/2026
Last report
May 11, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$1.60 / $1.52
+5.26%beat
Revenue / Est. (USD)
376.71M / 359.05M
+4.92%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
325.72M
354.26M
451.77M
376.71M
Cost of goods sold
63.90M
72.49M
110.67M
104.80M
Cost of revenue
63.90M
72.49M
110.67M
104.80M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41.61M
46.09M
63.33M
57.88M
Operating expense
59.38M
63.85M
86.70M
87.39M
Total operating expenses
123.28M
136.34M
197.37M
192.19M
Operating income
202.44M
217.92M
254.40M
184.52M
Other non operating income
6.89M
-
-
-
EBT including unusual items
204.94M
218.96M
-100.85M
180.33M
EBT excluding unusual items
204.94M
218.96M
251.58M
180.30M
Income tax expense
39.78M
43.73M
40.74M
30.28M
Effective tax rate
19.41%
19.97%
-40.40%
16.79%
Other operating expenses
-
-
-
-
Net income
165.16M
175.22M
-141.59M
150.05M
Net profit margin
50.71%
49.46%
-31.34%
39.83%
Earnings per share
1.54
1.72
-0.24
1.60
Interest and investment income
-
5.33M
2.09M
1.29M
Interest expense
-4.39M
-4.30M
-4.91M
-5.51M
Net interest expenses
-4.39M
1.04M
-2.82M
-4.22M
Depreciation and amortization charges
-
-
-
-
EBITDA
221.44M
236.84M
279.08M
215.65M
Gain or loss from assets sale
-
-
2.62M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer